← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
margetuximab
L01FD06
Forms & Strengths
- Injection: 250mg/10mL, 500mg/20mL
- Single-dose vial
Adult Dosing
- 15mg/kg IV every 3 weeks
- Premedication recommended
- Dose adjustments for adverse reactions
Pediatric Dosing
- Not established
- Clinical experience limited
Indications
- HER2-positive metastatic breast cancer
- Combination with chemotherapy
Mechanism of Action
- Recombinant humanized monoclonal antibody
- Targets HER2
- Mediates antibody-dependent cellular cytotoxicity
Contraindications
- None established
- Use with caution in pregnancy
Adverse Reactions
- Fatigue
- Nausea
- Diarrhea
- Infusion-related reactions
Drug Interactions
- Pertuzumab and trastuzumab for HER2-positive breast cancer
- Potential interactions with other monoclonal antibodies
Curated Content: Needs Vetting Before Put to Clinical Use